PathoVax LLC

1812 Ashland Ave, FastForward, Lab G25-0
Baltimore MD 21205
Share:
About Us
PathoVax is advancing a human papillomavirus (HPV) virus-like particle (VLP) technology developed at Johns Hopkins. Our lead patented vaccine, RGVax, is the first vaccine to target all 15 cancer-causing HPVs in a market with $2B+ annual revenues while offering the opportunity to be marketed as a pediatric vaccine to expand uptake. Current funding which includes an NCI contract worth $US5M provides an operating runway to IND approval in 2019, and we plan to complete our phase 1 human safety studies for strategic exits in 2021. Beyond this lead indication, HPV VLPs are robust carriers for novel antigens to induce targeted immune responses.
Powered By GrowthZone

MTC NEW MEMBERS